Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance

Abstract

The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluation Programme, for the management of bowel dysfunction. The company, Coloplast, submitted a case for adoption of the technology, claiming that the technology improves the severity of chronic constipation or faecal incontinence and improves quality of life for people with bowel dysfunction. Other claimed benefits included reduced frequency of UTIs, stoma surgery and hospitalisation rates, as well as reduced costs. The submission was critiqued by Cedar. The clinical evidence assessed included one randomised controlled trial, and 12 observational studies for adults and 11 studies for children. Although there are limitations in the evidence, the assessed studies show some improvement in outcomes for patients who choose to continue using Peristeen. The committee heard from patient experts that Peristeen had improved their lives and allowed them increased independence. The submitted economic evidence had numerous flaws, however following Cedar’s changes to the model, and additional sensitivity analysis, the use of Peristeen was judged unlikely to be cost incurring compared with standard bowel care. The Peristeen transanal irrigation system received a positive recommendation in Medical Technologies Guidance 36.

Key Points for Decision Makers

Peristeen is used by a wide range of people with bowel dysfunction from different causes.

Not all patients find Peristeen acceptable or useful; however, for those who do, it can be a significant improvement in their quality of life and can promote dignity and independence.

Peristeen can be difficult to use and people may require time, training and support to get comfortable with using it. Some people will choose to stop using Peristeen.

There are considerable uncertainties in the economic evaluation; however, on average, Peristeen is unlikely to cost more than standard bowel care over a relevant time horizon.

Introduction

The National Institute for Health and Care Excellence (NICE) produces guidance on new or innovative medical devices or diagnostics—Medical Technologies Guidance (MTG). The aim of the guidance is to support the adoption of clinically effective and cost-saving technologies in the UK National Health Service (NHS). The process for producing MTG has been previously described in detail [1].

This paper summarises Cedar’s assessment report and how it was used to inform the NICE MTG on the Peristeen transanal irrigation system to manage bowel dysfunction (MTG36). Cedar is a NHS–academic health care technology research collaboration based in Cardiff. This paper is part of a series that provides an insight into the development of NICE MTG [1].

Background to the Condition and Technology

Neurogenic bowel dysfunction can be caused by neurological conditions such as spinal cord injury, spina bifida, multiple sclerosis, Parkinson’s disease and other conditions associated with impairment or loss of sphincter control and bowel mobility disorders. Bowel dysfunction can also have numerous other causes, such as injury to the rectum or bowel, or slow transit constipation. Symptoms include faecal incontinence and constipation, along with an increased rate of urinary tract infections (UTIs).

Transanal irrigation can be used by people with bowel dysfunction to empty the rectum and some of the colon at a time and frequency that is suitable to them, and to avoid faecal incontinence and constipation.

Peristeen is a transanal irrigation system consisting of a rectal catheter with an inflatable balloon, a manual control unit with a pump, leg straps, and a bag to hold water. The constant flow pump means that the system does not depend on gravity, and the bag does not need to be elevated. A new catheter is required for every use. The manufacturer recommends use every other day, although users will develop their own preference for how frequently to use the irrigation system. Peristeen received a CE mark in May 2003 as a class 1 medical device.

A variety of systems, including Peristeen, are available that differ in design and use. These choices should be discussed by clinician and patient, and a number of systems may be tried before a preferred device for transanal irrigation is found for that particular patient.

Currently, alternative treatment options include medication (oral drugs, suppositories and enemas), changes to diet, and physiotherapy. People with bowel dysfunction may also manage their symptoms using biofeedback, bowel washouts and manual removal of faeces. Some patients may need or may prefer surgery, i.e. a colostomy, ileostomy, sacral nerve stimulation or an antegrade continence enema procedure.

The benefits claimed by the company to people with bowel dysfunction are that use of Peristeen improves symptoms/reduces the severity of chronic constipation; reduces the severity and frequency of faecal incontinence; improves quality of life for people with bowel dysfunction; and reduces the incidence of UTIs in people with neurogenic bowel dysfunction.

The benefits claimed by the company to the healthcare system are that the use of Peristeen reduces the rate of stoma surgery in people with neurogenic bowel dysfunction; reduces the frequency, and therefore the treatment costs, of UTIs; reduces the cost of treating neurogenic bowel dysfunction in people who have experienced unsuccessful standard bowel care as first-line treatment; and reduces the rate of hospitalisation in people with neurogenic bowel dysfunction.

Decision Problem (Scope)

In their evidence submission, the manufacturer must keep within the scope of the evaluation. The scope is defined by NICE in the form of a PICO table (population, intervention, comparator, outcomes, plus cost analysis and subgroups to be considered).

Population

The population was defined as people with bowel dysfunction in any setting. Although the company claims were based on neurogenic bowel disorder, following consultation NICE broadened the scope to include all bowel dysfunction. Cedar identified that the company had inappropriately excluded most studies on children, and included such studies in their report.

Intervention

The intervention was defined as the Peristeen transanal irrigation system.

Comparator

The comparator was defined as conservative bowel management, which can include treatments such as diet and bowel habit advice, medication, disposable pads and anal plugs, muscle/bowel training, biofeedback and electrostimulation, and digital stimulation and manual evacuation. It was noted that the type of treatment is dependent on personal preference, ability and carer support.

Outcomes

The following outcomes were included in the scope: severity and frequency of incontinence, severity of constipation, quality of life, length and frequency of irrigation, device-related adverse events, frequency of UTI, incidence of stoma surgery and hospitalisations, staff time (including primary care and community care visits), and individual length of use/user satisfaction.

Cedar’s Review of Evidence

The company provided an evidence submission to NICE that should be in line with the scope. This submission presented the available clinical and cost evidence, alongside a de novo cost model produced by the company. Cedar’s assessment report aimed to provide the Medical Technologies Advisory Committee (MTAC) with a balanced, fair, and independent appraisal of the evidence surrounding the use of Peristeen for bowel dysfunction [2]. Broadly, this involved (1) identifying any additional information not included in the manufacturer’s submission; (2) appraising the published clinical and cost evidence and, where necessary, presenting additional data; (3) critiquing the de novo cost model by checking inputs, assumptions, and structural integrity; (4) highlighting any key issues; and (5) presenting any new analyses carried out.

Review of Clinical-Effectiveness Evidence

The company submitted 10 studies consisting of 1 randomised controlled trial (RCT) of adults [3], 7 observational studies of adults [4–10], and 1 observational study of children [11], plus 1 prepublication study of adults. Cedar did not agree with the company’s justification for excluding all but one paediatric study (because they did not use validated scoring systems) and included all studies with relevant outcomes. Cedar undertook a comprehensive search and selection process (Fig. 1) and included a further 4 observational studies of adults[12–15] and a further 10 observational studies of children [16–25]. The main outcomes in the included studies were patient-reported outcomes, which, due to the nature of the device, was appropriate. Included studies are listed in Table 1.

Fig. 1.

Cedar’s study selection process. MHRA Medicines and Healthcare products Regulatory Agency, MAUDE manufacturer and user facility device experience

Table 1.

Studies included by both the company and Cedar

References	Country	Study type	Population	n	Company	Cedar
Adults
Chan et al. [12]	UK	OBS	Mixed	91	–	✓
Christensen et al. [4]	Europe including UK	OBSa	SCI	62	✓	✓
Christensen et al. [3]	Europe, including the UK	RCT	SCI	87	✓	✓
Del Popolo et al. [5]	Italy	OBS	SCI	36	✓	✓
Pre-publication study provided as ‘academic in confidence’					✓	✓
Hamonet-Torny et al. [6]	France	OBS	NBD	16	✓	✓
Kim et al. [13]	South Korea	OBS	SCI	52	–	✓
Loftus et al. [7]	Ireland	OBS	NBD	11	✓	✓
Nafees et al. [14]	UK	DC	Mixed	129		✓
Passananti et al. [8]	UK	OBS	MS	49	✓	✓
Preziosi et al. [9]	UK	OBS	MS	30	✓	✓
Rosen et al. [10]	Austria Switzerland	OBS	ARS	14	✓	✓
Whitehouse et al. [15]	UK	OBS	FBD	113	–	✓
Children
Alenezi et al. [16]	Saudi Arabia	OBS	NBD	18	✘	✓
Ausili et al. [17]	Italy	OBS	SB	60	✘	✓
Choi et al. [32]	South Korea	OBS	SB	44	✘	✘
Corbett et al. [18]	UK	OBS	Mixed	24	✘	✓
Kelly et al. [19]	USA	OBS	NBD	24	✘	✓
King et al. [20]	Australia	OBS	SB	20	✘	✓
Koppen et al. [21]	Netherlands	OBS	IC	67	✘	✓
Lopez Pereira et al. [22]	Spain	OBS	SB	40	✘	✓
Marzheuser et al. [23]	Germany	OBS	ARM	40	–	✓
Midrio et al. [11]	Italy	OBS	Mixed	83	✓	✓
Nasher et al. [24]	UK	OBS	IC	13	✘	✓
Pacilli et al. [25]	UK	OBS	Mixed	23	✘	✓

^aRCT and OBS paper by Christensen et al. used the same patients

ARM Anorectal malformation, FBD Functional bowel disorder, MS multiple sclerosis, SB spina bifida, SCI spinal cord injury, NBD neurogenic bowel dysfunction, IC idiopathic constipation, ARS anterior resection syndrome, RCT randomised controlled trial, OBS observational, single-arm study, DC discrete choice experiment, ✓ indicates included, ✘ indicates explicitly excluded

Adult Studies

One reasonable-quality RCT that included 87 adults with spinal cord injuries and neurogenic bowel dysfunction was identified [3]. This unblinded study compared transanal irrigation using Peristeen (n = 42) with standard bowel care (n = 45) for 10 weeks and reported significant improvements in validated patient-reported outcomes for bowel function. Twelve patients in the Peristeen arm and two standard care patients withdrew from the study. There was a significant improvement in a series of patient-reported outcome measures (PROMs)—Cleveland Clinic Constipation Scoring System (CCCS), St Mark’s Fecal Incontinence Grading System (FIGS), and Neurogenic Bowel Dysfunction Score (NBDS)—for the Peristeen group compared with standard care (Table 2).

Table 2.

Summary of RCTs

Included studies	Design and intervention(s)	Participants and setting	Outcomes	Results	Withdrawals	Cedar comments
Christensen et al. [3]	RCT comparing transanal irrigation using Peristeen with SBC for 10 weeks Company-funded	87 randomised (42 Peristeen vs. 45 SBC) 62 men, 25 women, average age 49.1 years 73 completed 5 European spinal cord injury centres (Sweden, Italy, Germany, UK, Denmark) All patients 18 years or older, at least 3 months after spinal cord injury	Primary outcomes  CCCS and FIGS Secondary outcomes  NBDS, modified ASCRS, numeric box score on bowel function, influence on daily activities and general satisfaction Outcomes collected at weeks 0 and 10, plus weekly telephone interview	CCCS, FIGS and NBDS were significantly improved for Peristeen vs. SBC Subgroup analysis found no significant difference for patients who could walk, but significant improvement for those who used wheelchairs or were confined to bed ASCRS scores were significantly improved for Peristeen vs. SBC in domains of coping/behaviour, but no significant difference was noted for the lifestyle and depression/self-perception domains The numeric box scores were significantly improved for bowel function, general satisfaction and improvement in quality of life, but not for influence on daily activities	14 w/d (12 Peristeen, 2 SBC) 73 completed, 5 lost to follow-up	Blinding was not possible A large number of patients stopped using Peristeen before the end of the study, and were subsequently included in ITT analysis using baseline data in place of missing data Baseline imbalance between groups for those using a wheelchair or confined to bed Subgroup analysis not stated as planned Study supported by the company

ASCRS American Society of Colon and Rectal Surgeons, CCCS Cleveland Clinic Constipation Score, FIGS St Mark’s Faecal Incontinence Grading Score, NBDS Neurogenic Bowel Dysfunction Score, SBC standard bowel care, RCTs randomised controlled trials, ITT intention to treat, w/d withdrawals

In the observational studies of adults, which reported comparative data (before and after), there was an improvement in patient-reported outcomes for bowel function when using Peristeen. Most of these studies used appropriate standardised PROMs. Outcome measures such as incidence of UTIs and faecal incontinence also improved when using Peristeen, while outcomes related to general quality-of-life measures were less widely reported and changes were either not significant or were significantly improved in only some domains. There were considerable numbers of people who stopped using Peristeen, particularly in the first few months.

Paediatric Studies

The paediatric studies were non-comparative, observational, case series. Six of these observational studies were prospective and five were retrospective in design. The studies were of variable quality and used less-consistent outcome measures. General findings indicated the use of Peristeen resulted in improvements in bowel management, however the evidence is weaker than for adults, partly due to the difficulty in obtaining valid PROM data for children.

For both adults and children, there were variable numbers of people who stopped using Peristeen, particularly in the first few months. This was frequently because they disliked using the device or found it painful or ineffective.

Safety Outcomes

Bowel perforation is a rare but potentially serious adverse event that can occur with Peristeen use. A global audit [26] based on voluntary reporting to the company found 49 incidents of bowel perforation, 35 of which were certainly caused by Peristeen. Less-serious adverse events include symptoms such as abdominal pain or nausea, which may lead individual patients affected to seek an alternative management strategy.

Review of Economic Evidence

The company identified two published economic studies [27, 28]. The Christensen et al. [27]. model is from a societal perspective, however it did not match the scope and was therefore excluded by both Cedar and the company. The work of Emmanuel et al. [28]. was the basis for the de novo cost model which is required from the company as part of the evidence submission, and is critiqued in the following sections. The company did not update the costs in the submitted model, but did comment on the impact the updated costs would have.

Model Structure

The submitted model was based on the work of Emmanuel et al. [28], a Markov model with a 6-month cycle, comparing the use of the Peristeen transanal irrigation system with standard bowel care for a 30-year-old subject with spinal cord injury. The model time horizon was 37 years, with a discount rate of 3.5% and an NHS and social services perspective. The available states in the model are management using Peristeen, standard bowel care, surgery, or stoma. Stoma is an end state in this model and patients cannot move from this, as shown in Fig. 2.

Fig. 2.

Markov model structure

Key assumptions in the model are as follows.

• All patients enter the model at age 30 and survive for 37 years. There is no death state in the model.

• The probability of ceasing to use Peristeen is assumed to be constant.

• Adverse events are included as hospital admissions, and are assumed to be split equally between gastrointestinal infections, pressure ulcers, falls or trauma, abdominal pain and UTI. Bowel perforation is not explicitly included.

• The model is stated as being for a patient with spinal cord injuries, and patients are assumed to be homogeneous.

• Transition probabilities and variables are constant over time for all patients. Many variables are likely to change with age for all patients, and will also change over time for patients with progressive diseases such as multiple sclerosis.

• Transition probabilities for patients who start using Peristeen and then revert to standard bowel care are stated in the submission as being the same as probabilities in the standard bowel care arm.

Data Sources for Outcomes and Resources

The model uses audit data for 227 patients from three UK hospitals as the main source of clinical and resource data. Data for standard bowel care are taken from the baseline questionnaires for patients, except for the number of patients progressing to stoma, which is taken from the retrospective data of 157 patients prior to the introduction of Peristeen. Limited information on the audit is published [8, 28], but an extract of some information was shared with Cedar by the company. The audit appears to have an appropriate NHS setting, with suitable patient pathways, and an appropriate, if heterogeneous, population. However, Cedar were unable to reconcile differences in the data from the available sources, and had insufficient information available to critique the audit data used in the model.

The statistical techniques used for calculating transition probabilities from patients enrolled at different time points, with different lengths of follow-up, were not stated.

Data Sources for Adverse Events

Adverse events are modelled as UTIs that respond to treatment, and events requiring hospitalisation. The hospitalisations are split equally between abdominal pain, gastrointestinal infection, pressure ulcers, falls and trauma, and UTIs. The assumption of an equal split is not justified and is likely to overestimate treatment for pressure ulcers, which can be very costly.

Errors

Cedar identified several errors in the model, the most important of which were all related to people in the Peristeen arm who returned to using standard care. The main errors for these people returning to standard care were:

• the cost of a health care professional’s time was not included;

• the cost of standard bowel care-related adverse events was not included;

• there was a lower use of consumables assumed, compared with people in the model who had never used Peristeen;

• a reduced probability of moving to surgery or stoma for people in the model receiving standard bowel care who had previously received Peristeen.

Cedar considered all these points to be modelling errors as they did not reflect the intended model function as described in the company submission. No evidence was submitted to suggest that people who used Peristeen and then changed back to standard care would have any different resource requirement or outcomes compared with those who had never used Peristeen. Once these errors were corrected, the cost saving due to the use of Peristeen was reduced from £21,768 to £7829.

Changes Made by Cedar

The change made by Cedar that had the largest impact was to change the cost of a pressure ulcer from £24,214 (Touche Ross [29], inflated) to £15,134 (Dealy [30], inflated). In addition, Cedar changed the cost of a UTI from £167.77 per episode to £52.57 (Berningham [31], inflated) in line with the costs listed in the original study referenced.

In order to reflect the high number of people ceasing to use Peristeen at an early stage, Cedar introduced a variable transition probability. Due to the limited data available, this was set as three different fixed values to empirically recreate the reported dropout rate. Background mortality was also added due to the long time horizon for this model.

The combined impact of these changes further reduced the cost saving to £3176, as shown in Table 3.

Table 3.

Impact on the incremental cost of additional work by Cedar

Model version	Incremental cost (over 37 years)
Base-case submitted by the company	− £21,768
Changes 1–8: correction of errors	− £7829
Patients in the Peristeen arm returning to SBC have full costs, including appropriate medication, HCP time and adverse events
Carer time in both arms is corrected
Transition probability for all patients receiving SBC is standardised
Changes 9–10: Cedar-suggested refinements	− £6976
9. Reduced number of Peristeen users in the first year, using variable transition probability
10. Background mortality added
11. Pressure ulcer cost changed to £15,134.84	− £3574
12. UTI cost changed to £52.57	− £3175
Final Cedar base-case with all corrections and refinements	− £3175

SBC standard bowel care, HCP healthcare professional, UTI urinary tract infection

One-Way Sensitivity Analysis

Cedar added frequency of use to the one-way sensitivity analysis and carried out additional sensitivity analysis.

The model is very sensitive to the frequency of use and also sensitive to pressure ulcer treatment and faecal incontinence, and there is uncertainty about each of these variables. There is limited clinical evidence around the frequency of use and for an improvement in faecal incontinence. Furthermore, there is no direct clinical evidence linking the use of Peristeen to a reduction in pressure ulcers.

Key Drivers

A key driver in the model is the frequency of use, due to the need for a new catheter at each use. The average frequency is likely to be correctly modelled every other day, however the actual use for each patient may vary from daily to weekly depending on their preferences and circumstances.

The cost saving identified in Cedar’s corrected model in the Peristeen arm is largely due to reduced time for health care professional visits and carer time; reduced incidence of faecal incontinence (requiring fewer incontinence pads); and reduced incidence of UTIs and fewer hospitalisations.

National NICE Guidance

Preliminary Guidance

The evidence submitted by the company and Cedar’s report were presented to the MTAC, who produced the following draft recommendations:

The case for adopting Peristeen for managing neurogenic bowel dysfunction in adults is supported by the evidence. Peristeen can reduce the severity of constipation and incontinence, improve bowel-related quality of life, and promote dignity and independence.

Peristeen may not be suitable for all people with neurogenic bowel dysfunction and can be difficult to use. It may take several weeks before a person is comfortable using it themselves, and some people may choose to stop using it. Peristeen is therefore most effective when it is offered with specialist training for users, carers and NHS staff, along with structured patient support.

Cost modelling for Peristeen is associated with significant uncertainties, but it is likely that, overall, Peristeen provides additional clinical benefits without costing more than standard bowel care.

Consultation Response

During the consultation period, NICE received 43 consultation comments from 18 consultees (9 NHS professionals, 1 private sector healthcare professional, 1 professional society, 1 patient group and 6 manufacturers). The comments related to Peristeen use in children, functional bowel disorders, user experience, other transanal irrigation devices, frequency of use, cost and adverse events. New information was submitted from centres using Peristeen in children and in people of all ages with functional bowel disease. This information was reviewed by Cedar and presented to the committee. Because of this, the committee broadened the recommendations to include people with bowel dysfunction of any age.

Key Challenges and Learning Points

The Peristeen transanal irrigation system can be used successfully by a wide range of people whose bowel dysfunction may have different causes and symptoms. This leads to a very broad scope, and the studies that inform the clinical evidence have diverse populations and outcomes. This breadth and diversity mean that combining the clinical evidence presents particular challenges. In addition, the outcomes most important to the people who use Peristeen may not be the outcomes that are most easily captured and reported in clinical studies.

The economic evaluation aspect presented significant challenges due to the lack of transparency in the data used for clinical and resource inputs, and the significant structural errors contained in the model. The focus of the sensitivity analysis on costs rather than resource use, and the omission of key factors, such as frequency of use, was potentially misleading.

Conclusions

The Peristeen transanal irrigation system received a positive recommendation from NICE and should be considered as an option for people requiring additional treatment strategies to manage bowel dysfunction. Published evidence showed that the Peristeen transanal irrigation system improved patient-reported outcomes in those patients who continued to use it. The evidence is more robust for the adult population, partially due to the availability of appropriate validated outcome measures. Consultation responses reported the successful use of Peristeen in children in the UK. The submitted economic evidence was based on audit data that were not available for scrutiny, and the model contained several errors. Despite the uncertainty that remains in the model, it is likely that use of the Peristeen transanal irrigation system will not cost any more than standard care.